Back to news

Genmab Gains After Phase 3 Ovarian Cancer Win for Rina-S

Investivoq PriceTracker

Genmab A/S (GMAB) is up 4.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is Genmab’s October 23, 2026 announcement that its experimental ovarian cancer drug Rina-S met both the main progression-free survival goal and a key overall survival goal in the Phase 3 RAINFOL-02 trial. That kind of late-stage oncology result can materially improve expectations for future regulatory filings, commercial potential, and the value of Genmab’s broader pipeline.

Details:

  • Genmab said Rina-S beat investigator’s choice chemotherapy in platinum-resistant ovarian cancer, with statistically significant improvement in both progression-free survival and overall survival.
  • The company disclosed a 71% reduction in the risk of disease progression or death in the intent-to-treat population, alongside a 57% reduction in the risk of death.
  • Management said the safety profile was consistent with prior experience and that no new safety signals or unexpected concerns were identified, which likely helped support investor confidence in the readout.
  • The update builds on recent momentum around the program, following earlier October data in ovarian cancer and solid DARZALEX royalty-linked sales that have kept attention on Genmab’s late-stage growth assets.

    • Sources:

    Genmab, Yahoo Finance, BioSpace

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    EARLY ACCESS
    Receive GMAB Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $GMAB Hedge Fund Activity

    We have seen 148 institutional investors add shares of $GMAB stock to their portfolio, and 120 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DEERFIELD MANAGEMENT COMPANY, L.P. added 6,865,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $188,581,550
    • PARADIGM BIOCAPITAL ADVISORS LP added 5,165,295 shares (+64.8%) to their portfolio in Q2 2026, for an estimated $141,890,653
    • SOFINNOVA INVESTMENTS, INC. added 3,292,954 shares (+437.7%) to their portfolio in Q2 2026, for an estimated $90,457,446
    • DEEP TRACK CAPITAL, LP added 1,986,750 shares (+54.2%) to their portfolio in Q2 2026, for an estimated $54,576,022
    • ORBIS ALLAN GRAY LTD removed 1,557,417 shares (-12.0%) from their portfolio in Q2 2026, for an estimated $42,782,244
    • TWO SIGMA INVESTMENTS, LP added 1,167,411 shares (+49.9%) to their portfolio in Q2 2026, for an estimated $32,068,780
    • QUBE RESEARCH & TECHNOLOGIES LTD added 1,011,938 shares (+149.4%) to their portfolio in Q2 2026, for an estimated $27,797,936

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.